VolitionRx Limited(VNRX)Earnings, Financials & Key Ratios

VNRX•AMEX

$1.40

Price updated Jul 7, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryMolecular and Genetic Diagnostics

AboutVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.Show more

Revenue$2M+40.0%
EBITDA-$20M+22.1%
Net Income-$23M+13.4%
EPS (Diluted)-4.40+29.0%
Gross Margin100%
EBITDA Margin-1158.15%+44.4%
Operating Margin-1228.57%+43.9%
Net Margin-1352.16%+38.2%

VNRX Price & Volume

VolitionRx Limited (VNRX) stock price & volume — 10-year historical chart

Loading chart...

Persistent Cash Burn Challenges Clinical Development Trajectory

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Severe liquidity and dilution

Key Thesis Takeaways

VolitionRx faces a precarious financial outlook characterized by a reliance on lumpy milestone payments and a structural inability to self-fund its aggressive R&D strategy.
While the company maintains high gross margins, the decoupling of operating expenses from revenue generation suggests a fundamental lack of commercial scale.
Investors should monitor the severe liquidity constraints and the potential for further dilutive capital raises as the company attempts to bridge its significant funding gap.

Verdict Logic

the company's current ratio of 0.17 and the depletion of total assets from $28.0 million to $6.9 million over two years signal extreme insolvency risk.

VNRX Growth Metrics

VolitionRx Limited (VNRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years164.15%

3 Years77.98%

TTM88.49%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-2.39%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM22.24%

Return on Capital

10 Years-173.86%

5 Years-263.15%

3 Years-311.79%

Last Year-

Latest VNRX News

Recent stock market news and headlines for VolitionRx Limited (VNRX)

PRNewsWire·21h ago

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly.

PRNewsWire·Jun 17, 2026

VolitionRx Announces Collaboration with Sysmex

HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.

Peers Comparison

Key metrics vs top competitors for VolitionRx Limited (VNRX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
VNRXVolitionRx LimitedCurrent	$1.40	$7.49M	-0.32	40.04%	-1352.16%	—	—
EXASExact Sciences Corporation	$104.91	$20.02B	-95.37	17.69%	-6.4%	-8.66%	—
ILMNIllumina, Inc.	$191.76	$29.13B	35.19	-0.78%	19.43%	32.84%	—
NTRANatera, Inc.	$281.27	$40.28B	-185.05	35.9%	-9.05%	-15.13%	—
GKOSGlaukos Corporation	$150.65	$8.82B	-45.93	32.33%	-34.34%	-26.46%	—
GHGuardant Health, Inc.	$162.92	$21.6B	-49.07	32.88%	-40.1%	—	—